Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Brandon Weiss, Induni Ginige, Lu Shannon, et al.
Psychological Medicine (2023) Vol. 54, Iss. 1, pp. 178-192
Open Access | Times Cited: 22

Showing 22 citing articles:

Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yuan Yao, Dan Guo, Tangsheng Lu, et al.
Psychiatry Research (2024) Vol. 335, pp. 115886-115886
Closed Access | Times Cited: 32
Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial
Broc A. Pagni, Richard J. Zeifman, Sarah E. Mennenga, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 114-125
Closed Access | Times Cited: 3
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up
Friederike Holze, Peter Gasser, Felix Müller, et al.
The British Journal of Psychiatry (2024) Vol. 225, Iss. 3, pp. 362-370
Open Access | Times Cited: 12
Exploring Serotonergic Psychedelics as a Treatment for Personality Disorders
Brennan M. Carrithers, Daniel E. Roberts, Brandon Weiss, et al.
Neuropharmacology (2025), pp. 110413-110413
Closed Access | Times Cited: 1
Psilocybin induces acute anxiety and changes in amygdalar phosphopeptides independently from the 5-HT2A receptor
Ram Harari, Ipsita Chatterjee, Dmitriy Getselter, et al.
iScience (2024) Vol. 27, Iss. 5, pp. 109686-109686
Open Access | Times Cited: 8
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition/creativity, emotional processing and personality
Ivana Solaja, Kate Haldane, Natasha L. Mason, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 158, pp. 105570-105570
Closed Access | Times Cited: 6
Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
Noah Chisamore, Danica E. Johnson, Margery J.Q. Chen, et al.
Journal of Psychiatric Research (2024) Vol. 176, pp. 77-84
Closed Access | Times Cited: 6
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review
Joshua Liebnau, Felix Betzler, André Kerber
Journal of Psychopharmacology (2025)
Open Access
Psychedelic-assisted Therapy as a Promising Treatment for Irritable Bowel Syndrome
Erin E. Mauney, Franklin King, Helen Burton Murray, et al.
Journal of Clinical Gastroenterology (2025)
Closed Access
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer’s disease comorbidities?
Michael Davidson, Gabriela Dumitriṭa Stanciu, Jonathan Rabinowitz, et al.
Dialogues in Clinical Neuroscience (2025) Vol. 27, Iss. 1, pp. 1-12
Open Access
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice
Eduardo Ekman Schenberg
Pharmacology Research & Perspectives (2025) Vol. 13, Iss. 2
Open Access
A retrospective analysis of combined treatment with escitalopram and Naoan dropping pills treatment for depression
Xiaoyan Wang, Yan Che, Wenli Wang
Medicine (2025) Vol. 104, Iss. 17, pp. e42169-e42169
Open Access
Stutterers’ experiences on classic psychedelics: A preliminary self-report study
Eric S. Jackson, Noam Goldway, Hope Gerlach, et al.
Journal of Fluency Disorders (2024) Vol. 81, pp. 106062-106062
Closed Access | Times Cited: 3
Assessing potential of psilocybin for depressive disorders
Zofia Kozak, Matthew W. Johnson, Scott T. Aaronson
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 10, pp. 887-900
Closed Access | Times Cited: 8
A Critical View on New and Future Antidepressants
Alessandro Serretti
Clinical Psychopharmacology and Neuroscience (2024) Vol. 22, Iss. 2, pp. 201-210
Open Access | Times Cited: 2
The Effect of Psychedelics on Individuals with a Personality Disorder: Results from two Prospective Cohort Studies
Alexandra R. Gordon, Brennan M. Carrithers, Broc A. Pagni, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 2
An investigation of acute Physiological and Psychological Moderators of Psychedelic-induced Personality Change among Healthy Volunteers
Kate Godfrey, Brandon Weiss, Xinwei Zhang, et al.
Neuroscience Applied (2024), pp. 104092-104092
Open Access | Times Cited: 1
Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression – CORRIGENDUM
Brandon Weiss, Induni Ginige, Lu Shannon, et al.
Psychological Medicine (2023) Vol. 54, Iss. 1, pp. 217-217
Open Access | Times Cited: 1
The Therapeutic Effects of Classic Psychedelics in Alcohol Use Disorder
Broc A. Pagni, Jonathan M. Wong, Michael P. Bogenschutz
Current Addiction Reports (2024) Vol. 11, Iss. 5, pp. 916-927
Closed Access
The Use of Classic Psychedelics for Depressive and Anxiety-Spectrum Disorders
Vivian Kim, Scott Wilson, Mary E. Woesner
Journal of Clinical Psychopharmacology (2024)
Closed Access
Psychopharmacological treatment of depression and anxiety and their different drug delivery targets
Aditya Sharma, Md. Aftab Alam, Awaneet Kaur, et al.
Current Psychiatry Research and Reviews (2023) Vol. 20, Iss. 4, pp. 297-322
Closed Access
Page 1

Scroll to top